Replies to post #278538 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

If it works out Dr. Vamvakides will be recognised for his invention and Dr. Missling for getting it to market.

Geneva, Switzerland — January 31, 2007

Under the terms of the acquisition, Anavex is to pay for the development of the compounds by expending not less than $200,000 US per annum. Dr. Vamvakides will lead the development project and will receive 6% royalties on the total net income resulting from successful exploitation of the assigned patents. The Company endeavors to further develop the appropriate compounds utilizing various research facilities worldwide.

Hoepfully for Dr. Vamvakides this agreement is still in force regardless of the patent being expired. I would swap my current $AVXL position for the Vamvakides deal.

[Blur]

Expect stair stepping until the hint of serious bio fund buying

If there is any sign before the EOY ....


IMO